Article

BioLight subsidiary files IND for glaucoma treatment

BioLight Israeli Life Sciences Investments’ subsidiary, ViSci, has filed an investigational new drug (IND) application with the FDA to conduct a phase I/IIa clinical study with its treatment for glaucoma-a subconjunctival Latanoprost controlled-release insert.

 

Tel-Aviv, Israel-BioLight Israeli Life Sciences Investments’ subsidiary, ViSci, has filed an investigational new drug (IND) application with the FDA to conduct a phase I/IIa clinical study with its treatment for glaucoma-a subconjunctival latanoprost controlled-release insert.

The 3-month study in 68 glaucoma patients will be designed to prove the safety and efficacy of different doses of the insert containing its proprietary form of latanoprost.

Pending FDA approval, the study will be conducted at up to seven investigative sites in the United States.

Recently, ViSci has successfully completed an ocular toxicology and safety study in animals, and it holds an exclusive option from Novaer LLC to a worldwide exclusive license for any use of the insert’s controlled-release technology with any medication.

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.